abstract: INTRODUCTION: In the past 10 years, @entity7248 has been associated with other comorbidities and neurologic and @entity146 conditions in particular. Case series, small case-control studies, and large population-based studies in different Asian populations, mainland Europe, and the United Kingdom have confirmed this association. However, no data are available for the Spanish population. MATERIAL AND METHODS: This was an observational, retrospective, case-control study with 1:2 matching. Fifty-four @entity1 with @entity7248 were selected. We compared the percentage of @entity1 in each group with concurrent @entity16 , @entity741 , @entity6 , @entity5 using univariate logistic regression. An association model was constructed with conditional multiple logistic regression. RESULTS: The case group had a significantly higher percentage of @entity1 with @entity64 and/or transient @entity63 attack (odds ratio [OR], 3.06; 95% CI, 1.19-7.87], @entity303 (OR, 5.52; 95% CI, 2.19-13.93), and @entity191 (OR, 5; 95% CI, 1.57-15.94). A significantly higher percentage of cases had @entity16 (OR, 6.34; 95% CI, 2.89-13.91). @entity303 and @entity191 were independently associated with @entity7248 in the multivariate analysis. CONCLUSIONS: @entity1 with @entity7248 have a higher frequency of @entity16 .

title: Association Between Bullous Pemphigoid and XXXX : A Case-Control Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['cerebrovascular accident']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['chronic obstructive pulmonary disease, and solid tumors']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic conditions']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['Dementia', 'dementia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['Parkinson disease']

entities_list: @entity7248 :: ('MESH:D010391', 'Disease') :: ['bullous pemphigoid']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease']

answer: @entity16 :: (MESH:D009422,Disease) :: ['Neurologic Diseases']


abstract: OBJECTIVE: The @entity29766 , @entity23662 and @entity40230 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus associated with a prevalence of @entity1187 ( @entity1187 ). Reports concerning their association with long-term outcome after an @entity1187 are equivocal. The aim of our study was to investigate the association of the 9p21.3 locus with 5-year overall mortality in @entity1 with @entity583 ( @entity583 ). MATERIALS AND METHODS: We performed a retrospective analysis of data collected prospectively in 2 independent registries of consecutive @entity1 with @entity583 (derivation and validation group). Genotyping was performed with the TaqMan method. The analyzed end-point was total mortality. RESULTS: The derivation group comprised 589 @entity1 : 25.3% female (n = 149), mean age 62.4    12.0 years, total 5-year mortality 16.6% (n = 98). When all the study group was analyzed, no significant differences in mortality were found between the genotypes. However, in high-risk @entity1 (GRACE risk score >=  155 points, n = 238), homozygotes associated with higher risk for @entity1187 had significantly better 5-year survival compared to other genotypes. The hazard ratio associated with the high-risk genotype (a homozygote of high risk for @entity1187 or a heterozygote) was: HR = 2.2 (1.15-4.2) for the @entity29766 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the @entity40230 one and HR = 2.3 (1.2-4.5) for the @entity23662 one (Cox proportional hazards model). Survival analysis in the validation group (n = 365) showed a clear trend towards better prognosis in GG homozygotes of the @entity29766 SNP, which confirms our initial results (p = 0.09, log-rank test). CONCLUSIONS: The 9p21.3 locus is associated with 5-year mortality in high-risk @entity1 with @entity583 . The genotypes associated with higher risk for @entity1187 show a protective effect in terms of further survival (instead of a deteriorating prognosis, as reported previously). This finding, due to the very high size of the effect, could potentially be applied to clinical practice, if appropriate methods are elaborated.

title: Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk XXXX with @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndromes']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-elevation myocardial infarction']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: In @entity1980 , the nit-3 gene, which encodes @entity1507 reductase, an enzyme required for the utilization of inorganic @entity1507 , is subject to a high degree of genetic and metabolic regulation as a member of the @entity1568 control circuit. The nit-3 gene promoter contains binding sites for a globally acting protein NIT2 and a pathway-specific protein NIT4. Expression of the nit-3 gene absolutely requires both the NIT2 and NIT4 transcription factors and only occurs under conditions of @entity1568 source derepression and @entity1507 induction. In the sulfur control circuit, the cys-14 gene encodes @entity597 permease II, which facilitates the assimilation of @entity597 . Expression of cys-14 is strongly regulated by only a single positive-acting factor, CYS3. It was of interest to determine whether NIT2 or NIT4 alone was capable of turning on the expression of cys-14, since this structural gene is normally controlled by only one regulatory protein. NIT2- and/or NIT4-binding elements were introduced into the promoter of a wild-type cys-14 gene and these constructs were transformed into a cys-13(-) cys-14(-) mutant strain and into a nit-2(-) mutant host. We examined whether any of these cys-14 genes in these transformants could now be controlled as a @entity1568 -regulated gene. @entity597 permease assays revealed that both NIT2 and NIT4 were required for cys-14 expression upon @entity1507 induction, while neither alone activated any detectable cys-14 expression. We thus conclude that neither NIT2 nor NIT4 is capable alone of activating gene expression in this context, but together they can cooperate to elicit strong activation.

title: Cooperative action of the NIT2 and NIT4 transcription factors upon gene expression in XXXX .

entities_list: @entity1980 :: ('5141', 'Species') :: ['Neurospora crassa']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate', 'Sulfate']

answer: @entity1980 :: (5141,Species) :: ['Neurospora crassa']


abstract: Few @entity1 with metastatic @entity356 have disease that is amenable to curative surgery. Thus far, little is known about liver surgery for @entity3 arising from @entity356 and prognostic factors. Of 73 @entity1 operated on between 1980 and 1999 for noncolorectal, @entity99 , 15 underwent liver resection for @entity356 @entity3 . Ten @entity1 underwent synchronous hepatic resection and five underwent metachronous hepatic surgery after a median disease-free interval of 10 months (range 6.1 to 47.3 months). None of the @entity1 died within the first 30 days after surgery, and the in-hospital mortality rate was 6.7%. Among @entity1 in the synchronous group, 26.7% experienced major complications mainly associated with gastric surgery. Overall median survival was 8.8 months (range 4 to 51 months); two @entity1 survived more than 3 years. Univariate analysis revealed that the appearance of liver @entity3 (synchronous vs. metachronous), the distribution of liver @entity3 (unilobar vs. bilobar), and the primary @entity5 site (proximal vs. distal) were marginally significant predictive factors regarding overall survival. Because of its high morbidity, synchronous liver resection for @entity3 originating from @entity356 is rarely followed by survival longer than 2 years. @entity5 localization within the proximal third of the stomach and bilobar liver involvement appear to be predictive of poor outcome. On the other hand, curative resection of metachronous liver @entity3 may allow long-term survival in selected @entity1 .

title: Analysis of hepatic resection of XXXX originating from @entity356 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Primary tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['non-neuroendocrine hepatic metastases']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric adenocarcinoma']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']


abstract: UNASSIGNED: In this work the development of an experimental protocol to perform the in situ gel-paving of coronary stent is presented. Biocompatible aqueous blends of Pluronic F127 and sodium alginates are used as potential drug dosage system for pharmacological in situ treatment of @entity256 . Pluronic F127/alginate aqueous blend has the unique characteristic to be liquid at room condition and to form gel at physiological temperature. The proposed protocol is based on the blend injection on stent wall previously implanted in a flexible silicon pipe mimicking the coronary artery. Injected blend is warmed up until @entity1 body temperature achieving a soft gel, then it is reticulated by copper bivalent ions to obtain an hard gel. To test the gel paving resistance to @entity2681 phenomena when it is exposed to fluid flux (i.e. blood flux) a dedicated device, (the Simulated Artery Device, @entity4696 ), was built to simulate the @entity1 circulatory apparatus. The @entity4696 is an hydraulic circuit in which a buffer solution (at pH 7.4) was fluxed by a peristaltic pump through the pipe hosting the covered stent. Erosion tests were performed monitoring, by gravimetric and spectrophotometric methods, the residual mass anchored to stent mesh after given times. The obtained results showed that the in situ gel-paving developed protocol was efficacious and reliable. The gel-paving was completely eroded in a time of the same order of magnitude of the physiological period required to restore the coronary lesion (subsequent to the @entity1856 removal) and of a pharmacological therapy to inhibit the in-stent-restenosis pathology.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2015.

title: In situ coronary stent paving by Pluronic F127-alginate gel blends: Formulation and XXXX tests.

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['coronary in-stent restenosis']

answer: @entity2681 :: (MESH:D014077,Disease) :: ['erosion']


abstract: OBJECTIVE: To examine the trajectory of uncertainty and symptoms of @entity1642 during the first 3 months after coronary angioplasty and coronary bypass surgery and to study the impact of social support on uncertainty and @entity1642 in these @entity1 populations. DESIGN: Descriptive, correlative. SETTING: Urban community, at-home interviews. @entity1 : Male @entity1 with angioplasty (n = 22) and bypass (n = 25) at 1 and 3 months after treatment. Age range was 39 to 75 years (mean 58 years). OUTCOME MEASURES: Mishel Uncertainty in Illness scores, General Health Questionnaire scores, and Perceived Social Support Scale scores. INTERVENTION: @entity1 underwent either percutaneous transluminal coronary angioplasty or coronary artery bypass grafting as treatment for @entity453 . RESULTS: Data were analyzed with repeated measures analysis of variance and Pearson correlation coefficients. Results showed that at both time periods angioplasty @entity1 were more uncertain than bypass @entity1 (p < 0.05), and that regardless of procedure, @entity1 reported fewer symptoms of @entity1642 at 3 months than at 1 month (p < 0.01). @entity1 with high social support had less uncertainty and @entity1642 than @entity1 with low support (p < 0.05). Analysis of the social support and treatment group interaction showed that angioplasty @entity1 with low perceived social support had significantly more @entity1642 than angioplasty @entity1 with high support (p < 0.01). Analysis of the correlations between uncertainty and @entity1642 in the angioplasty and bypass grafting procedure groups after control for social support revealed that social support was a significant mediator of the relationship between uncertainty and stress only among @entity1 undergoing percutaneous transluminal coronary angioplasty. There was little evidence of a mediating role for social support in the coronary artery bypass grafting group. CONCLUSIONS: These results suggest that angioplasty @entity1 may be in particular need of interventions aimed at reducing uncertainty, and that interventions that increase social support could be important in achieving this reduction.

title: Uncertainty and XXXX after coronary angioplasty and coronary bypass surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity1642 :: ('MESH:D015775', 'Disease') :: ['psychologic stress']

answer: @entity1642 :: (MESH:D015775,Disease) :: ['psychologic stress']


abstract: BACKGROUND AND PURPOSE: We aimed to assess the interaction between @entity5275 ( @entity5275 ) and @entity432 on acute cervicocerebral computed tomographic angiography on the outcome of @entity1 with acute @entity385 . METHODS: @entity1 from the Acute @entity64 Registry and Analysis of Lausanne (ASTRAL) registry with onset-to-door-time  <=4 hours, acute cervicocerebral computed tomographic angiography, a premorbid modified Rankin Scale  <=2, and a National Institute of Health @entity64 Scale (NIHSS) >4 were selected. @entity1 with significant intracranial @entity432 (>= 50%-99%) and undergoing acute endovascular treatment were excluded. An interaction analysis of @entity5275 and initial @entity432 for favorable 3 months outcome (modified Rankin Scale <3) were performed with adjustment for potential confounders. RESULTS: Among 654 included @entity1 , 382 (58%) showed @entity432 , of whom 263 (69%) received @entity5275 . Two hundred seventy-two showed no/minimal obstruction of whom 139 (51%) received @entity5275 . In the adjusted interaction analysis, there was a trend in favor of the @entity432 group (odds ratio [OR]=3.97; 95% confidence interval [CI], 0.83-18.97; P=0.08). @entity5275 (versus no @entity5275 ) was associated with better outcome in @entity1 with @entity432 (adjusted OR for favorable outcome, 3.01; 95% CI, 1.10-8.28) but not in @entity1 with no/minimal obstruction (OR, 0.76; 95% CI, 0.21-2.74). Conversely, @entity1 with @entity432 had a similar rate of favorable outcome as no/minimal obstruction when thrombolysed (OR, 0.5; 95% CI, 0.17-1.47) but had a less favorable outcome without thrombolysis (OR, 0.13; 95% CI, 0.04-0.44). CONCLUSIONS: In this retrospective analysis of consecutive @entity1 with acute @entity385 , there was a trend for more favorable outcomes with @entity5275 in the setting of initial @entity432 than in the setting of no/minimal obstruction. Before confirmation in randomized controlled studies, this information should not influence thrombolysis decisions, however.

title: Influence of XXXX on outcome after @entity5275 for acute @entity385 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5275 :: ('MESH:D015819', 'Disease') :: ['IVT', 'intravenous thrombolysis']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['occlusion', 'arterial obstruction', 'arterial occlusion']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity432 :: (MESH:D001157,Disease) :: ['arterial occlusion']


abstract: BACKGROUND _ OBJECTIVE: Full-length form of spleen @entity669 kinase [ @entity10255 (L)] is a @entity5 suppressor gene in @entity0 , which may translocate into cell nucleus and act as a transcriptional repressor. This study was to explore the mechanism of @entity10255 (L) regulated gene transcription in @entity0 cells. METHODS: Flag-tagged @entity10255 (L) was transfected into @entity1 embryonic kidney (HEK) 293 cells, and the interaction of @entity10255 (L) and histone deacetylases (HDACs) was detected by immunoprecipitation. The binding of endogenous @entity17029 and @entity10255 (L) in @entity0 cell line MB468 was also detected by immunoprecipitation. Flag-tagged @entity10255 (L) domains SH2, @entity573 , and IDB(L) were transfected into HEK293 cells, respectively, and their interaction with @entity17029 was detected. The activity of HDACs in the immunoprecipited complexes of @entity10255 (L) was tested by HDAC activity detecting system. RESULTS: Exogenous @entity10255 (L) was bound with @entity17029 , 3, 6, and 7 in HEK293 cells, and endogenous @entity10255 (L) was bound with @entity17029 in MB468 cells. @entity3958 and @entity573 , but not IDB(L), were coimmunoprecipitated with @entity17029 . The activity of HDACs was detected in the immunoprecipited complexes of @entity10255 (L). CONCLUSIONS: @entity10255 (L) regulates gene transcription in @entity0 by binding with HDACs to form transcription repressive complexes.

title: [Biological mechanism of full-length form of spleen @entity669 kinase regulating gene transcription in XXXX cells].

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: PURPOSE: The presence of disseminated @entity5 cells (DTCs) in bone marrow (BM) predicts survival in early @entity0 . This study explores the use of DTCs for identification of @entity1 insufficiently treated with adjuvant therapy so they can be offered secondary adjuvant treatment and the subsequent surrogate marker potential of DTCs for outcome determination. @entity1 AND METHODS: @entity1 with early @entity0 who had completed six cycles of adjuvant @entity1487 , @entity1259 , and @entity786 (FEC) chemotherapy underwent BM aspiration 2 to 3 months (BM1) and 8 to 9 months (BM2) after FEC. Presence of DTCs in BM was determined by immunocytochemistry using pan-cytokeratin monoclonal antibodies. If one or more DTCs were present at BM2, six cycles of @entity1205 (100 mg/m(2), once every 3 weeks) were administered, followed by @entity9856 analysis 1 and 13 months after the last @entity1205 infusion (after treatment). Cox regression analysis was used to evaluate @entity66 ( @entity66 ). RESULTS: Of 1,066 @entity1 with a DTC result at BM2 and available follow-up information (median follow-up, 71.9 months from the time of BM2), 7.2% were DTC positive. Of 72 @entity1205 -treated @entity1 analyzed for DTCs after treatment, 15 (20.8%) had persistent DTCs. @entity1 with remaining DTCs had markedly reduced @entity66 (46.7% experienced relapse) compared with @entity1 with no DTCs after treatment (adjusted hazard ratio, 7.58; 95% CI, 2.3 to 24.7). The @entity1205 -treated @entity1 with no DTCs after treatment had comparable @entity66 (8.8% experienced relapse) compared with those with no DTCs both at BM1 and BM2 (12.7% experienced relapse; P = .377, log-rank test). CONCLUSION: DTC status identifies high-risk @entity1 after FEC chemotherapy, and DTC monitoring status after secondary treatment with @entity1205 correlated strongly with survival. This emphasizes the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in @entity0 .

title: Clinical Outcome With Correlation to Disseminated XXXX Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With @entity1205 in Early @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['disease-free interval', 'DFI']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Tumor']


abstract: BACKGROUND: Although most @entity1 and young adults with @entity565 are atopic, exacerbations of @entity565 are frequently associated with viral @entity1729 , especially those caused by rhinovirus (HRV). OBJECTIVE: Young atopic adults with mild @entity565 were evaluated before and during an experimental HRV @entity281 to test the hypothesis that @entity32 before virus inoculation may be a risk factor for an adverse response to HRV. METHODS: @entity281 were evaluated in 16 @entity56 volunteers with mild @entity565 and 9 nonatopic control @entity1 (age, 18 to 30 years). Before virus inoculation, each @entity1 was screened with tests for lung function, prick skin tests for sensitization to common aeroallergens, measurements of total serum IgE, and serum neutralizing antibody to @entity1692 (the serotype used for inoculation). The response to @entity281 was monitored for 21 days by using symptom diary cards, tests for lung function, and markers of @entity32 in nasal washes, blood, and expired air. RESULTS: During the @entity281 , @entity748 @entity1 had cumulative upper and lower respiratory tract symptom scores that were significantly greater over the course of 21 days than scores from the control @entity1 . At baseline, the @entity748 @entity1 also had increased sensitivity to @entity2710 and significantly lower values for FEV(1) (percent predicted) than the control @entity1 (geometric mean and intraquartile values: 87% [79% to 91%] for the @entity748 @entity1 and 101% [90% to 104%] for the control @entity1 , P <.03). Among the @entity1 with mild @entity565 , 6 had levels of total serum IgE that were substantially elevated (range, 371 to 820 IU/mL) compared with 10 who had lower levels (range, 29 to 124 IU/mL). Those with high levels of IgE had significantly greater lower respiratory tract symptom scores during the initial 4 days of the @entity281 than the low IgE group. They also had higher total blood eosinophil counts at baseline, increased eosinophil cationic protein in their nasal washes (>200 ng/mL), and augmented levels of expired @entity842 at baseline and during peak cold symptoms. In contrast, levels of soluble intracellular adhesion molecule-1 in nasal wash supernatants from the @entity748 @entity1 with high IgE were diminished, both at baseline and during the @entity281 . CONCLUSIONS: The reduced lung function and increased markers of @entity32 observed before virus inoculation in the @entity748 @entity1 who had high levels of total serum IgE may be risk factors for an adverse response to infections with HRV.

title: Experimental rhinovirus challenges in adults with mild @entity565 : response to XXXX in relation to IgE.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'participant']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'airway inflammation']

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'Experimental HRV infections']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory tract infections']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine']

answer: @entity281 :: (MESH:D007239,Disease) :: ['infection']


abstract: A 48-year-old @entity1 required mechanical ventilation after aortic valve replacement for decompensated @entity472 when @entity548 complications developed and rethoracotomy had to be performed. @entity810 necessitated haemodialysis. Septic @entity221 of unknown aetiology failed to respond to @entity6101 , @entity3524 and @entity2890 . The endotracheal cannula and central venous catheter were changed on the 24th postoperative day and the antibiotic treatment altered to 250 mg @entity2892 and 125 mg @entity2176 three times daily intravenously. The @entity221 soon subsided, but recurred on the 32nd postoperative day, accompanied by @entity101 . The @entity1 was obstipated but had no intraabdominal signs. Four days later ultrasonography demonstrated thickening of the intestinal wall and coloscopy showed typical @entity8307 . Intestinal contents were positive for @entity2718 toxin. Despite immediate rectal and intragastric administration of 250 mg @entity2176 four times daily the @entity1 died of @entity8307 , confirmed at autopsy. The case demonstrates that @entity2176 cannot always prevent the development of @entity8307 .

title: [A lethal course in @entity8307 during the parenteral administration of @entity2176 and XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem']

entities_list: @entity2890 :: ('MESH:D014031', 'Chemical') :: ['tobramycin']

entities_list: @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['increasing leucocytosis']

entities_list: @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxim']

entities_list: @entity6101 :: ('MESH:D010068', 'Chemical') :: ['oxacillin']

entities_list: @entity8307 :: ('MESH:D004761', 'Disease') :: ['pseudomembranous colitis']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['Acute renal failure']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic valve stenosis']

entities_list: @entity2718 :: ('1496', 'Species') :: ['Clostridium difficile']

answer: @entity2892 :: (MESH:D015378,Chemical) :: ['imipenem']


abstract: The relationship between @entity3147 and @entity32 is by now well established. @entity650 and, probably, other proinflammatory cytokines (mainly @entity10960 ) may represent the link between these two entities since these interleukins may promote @entity1277 , muscle protein breakdown and reduced hepatic synthesis of "negative" acute phase proteins like albumin, prealbumin and @entity69 . @entity650 also stimulates up to 1000 fold the hepatic synthesis of "positive" acute phase proteins, mainly @entity1851 (CRP) and Serum Amyloid A. The association between CRP and cardiovascular mortality in the general population, as well as in haemodialysed uraemic @entity1 , is well established. These crucial interrelationships have modified the interpretation of serum albumin concentration in the diagnosis of @entity3147 ; a reduced serum albumin concentration, in fact, in the presence of high CRP values should point towards a diagnosis of @entity32 , though the @entity32 may often induce @entity353 or a condition of @entity3147 . After switching most @entity1 to a more biocompatible dialysis membrane and improvement of the quality of the dialysis fluid (by adopting hydrophobic filters at the water entry of dialysis devices and @entity3157 powder cartridges) nephrologists have focused their attention on other sources of @entity32 (e.g. artificial vascular protheses, presence of infected thrombi, Clamidiae, Helicobacter Pilori, dental @entity738 etc.). Starting from these assumptions the diagnosis of @entity3147 , once focused mainly on serum albumin reduction, must be based on other parameters (clinical history of body mass wasting, dietary and anthropometric assessment, subjective global assessment, bioimpedance analysis etc.). All these investigations, however, must be examined together to obtain suitable information on the risk of @entity3147 in dialysis @entity1 . A comprehensive approach to @entity32 in dialysis @entity1 is the object of the present nephrology conference.

title: [Predictive and diagnostic factors of XXXX in hemodialysis @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['malnutrition-inflammation', 'inflammation']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity3157 :: ('CHEBI:17544', 'Chemical') :: ['bicarbonate']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['loss of appetite']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive Protein']

answer: @entity3147 :: (MESH:D044342,Disease) :: ['malnutrition']


abstract: OBJECTIVES: The aim of this study was to investigate the associations between plasma total antioxidant capacity ( @entity11636 ) and anthropometric, biochemical, clinical, and dietary measurements in young and apparently healthy individuals. METHODS: We evaluated 156 individuals (91 @entity1 and 65 @entity1 ; ages 23.1    3.5 y; body mass index 22    2.9 kg/m(2)) for anthropometrics, biochemical markers, clinical, dietary, and some components of the antioxidant defense system, including the plasma @entity11636 . Statistical analyses were performed to detect differences between individuals with @entity11636 higher and lower than the mean value and to screen the associations between @entity11636 and variables of interest. A linear regression model was fitted to identify @entity11636 predictors. RESULTS: Daily caloric intake and macronutrient consumption were lower in individuals who exhibited the highest @entity11636 values (P < 0.05). Linear regression analysis showed that daily calories and @entity1735 intake was a possible negative @entity11636 predictor (P < 0.05). Nevertheless, there was no difference in the values of oxidized low-density lipoprotein in the individuals separated by means of @entity11636 . In contrast, individuals whose plasma @entity11636 values were above the mean showed higher low-density lipoprotein @entity165 concentrations, total @entity165 /high-density lipoprotein @entity165 values, and @entity4259 in nails (P < 0.05). CONCLUSIONS: In physiological conditions, the caloric intake level seems to be an important factor to act in the modulation of plasma @entity11636 , before establishing @entity209 , or both. Additionally, the plasma @entity11636 increase may be able to act as a compensatory mechanism.

title: Low energy and XXXX intake associated with higher total antioxidant capacity in apparently healthy adults.

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['anthropometric impairments of body or metabolic composition']

entities_list: @entity4259 :: ('MESH:D012643', 'Chemical') :: ['selenium']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1735 :: (CHEBI:16646,Chemical) :: ['carbohydrate']


abstract: Destruction of the medial preoptic area (MPOA) eliminates mating in male @entity35 and this region is believed to play a major role in the control of male sexual behavior. Efferents from the MPOA pass through and/or terminate in 4 midbrain regions: the dorsolateral tegmentum (DLT), the central gray, and the A9 and A10 areas. The present study reports the effects of bilateral destruction of each of these midbrain regions on brain @entity2661 and sexual behavior in male @entity35 . DLT lesions eliminated mating, reproducing the effect of bilateral preoptic lesions. The sexual activity of males with central gray lesions was accelerated in the sense that the mounting rate for these males was significantly faster than for controls and lesioned males ejaculated more frequently and with shorter latencies than did controls. @entity75 impaired mating--lesioned males mounted at a slower rate and ejaculated less frequently than controls. Males with A10 lesions took longer to re-initiate mating after an ejaculation than controls, but copulation per se (as reflected in mount rate, ejaculation frequency and latency to ejaculate) was not affected by A10 damage. Brain @entity2922 levels were not affected by either DLT or central gray lesions. @entity75 produced a significant depletion in neostriatal @entity935 which was highly correlated with mount latency, mount rate, ejaculation latency and ejaculation frequency. A10 lesions produced a significant depletion of @entity935 in the nucleus accumbens and cingulate cortex, but these effects were not significantly correlated with any measure of sexual behavior.

title: XXXX , @entity935 and male sexual behavior.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['A9 lesions']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine']

entities_list: @entity2661 :: ('MESH:D002395', 'Chemical') :: ['catecholamines']

answer: @entity75 :: (MESH:D001927,Disease) :: ['Midbrain lesions']


abstract: INTRODUCTION AND AIMS: Few general population studies have examined connections between harms and the social contexts where @entity1 drink. We examine how the dominant characteristics of respondents' latest drinking occasions are associated with self-reported @entity285 -related harm and to what extent the associations function over and above the effects of drinking patterns. DESIGN AND METHODS: We used a general population sample of Finns aged 15-69 years in 2008 (n   =   2725, response rate 73.6%). Data from 2362 respondents detailed the characteristics of drinking occasions, such as circumstance, location, company and timing for 8713 recent drinking occasions. Harms analysed were @entity146 (fights and arguments while drinking) and being asked to cut down on drinking by family members (informal control of drinking). RESULTS: With drinking patterns held constant, fights and arguments were more common among @entity1 whose drinking occasions started early or were described as 'visits', and among @entity1 where occasions ended late or occurred in mixed-gender groups. Requests to cut down were less frequent among @entity1 drinking mostly in connection with sauna bathing and meals or in single-gender company and among @entity1 who mostly drank in licensed premises or at weekends. Requests to cut down were more common among @entity1 drinking mostly in the company of friends. DISCUSSION AND CONCLUSIONS: Fights and arguments were associated with the timing of drinking occasions and some characteristics related to social interaction, while requests from family members to cut down were common when drinking extended beyond special occasions. [M  kel   @entity8075 , Mustonen Heli, Lintonen Tomi. The connection between drinking context choices and self-reported @entity285 -related social harm: Results from the Finnish drinking habit survey 2008. Drug @entity285 Rev 2015].

title: Connection between drinking context choices and self-reported XXXX -related social harm: Results from the Finnish Drinking Habit Survey 2008.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'people', 'men']

entities_list: @entity285 :: ('D000431', 'Chemical') :: ['alcohol', 'Alcohol']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive behaviour']

answer: @entity285 :: (D000431,Chemical) :: ['alcohol']


abstract: Asthma is one of the foremost contributors to morbidity and mortality in industrialized countries. Our objective was to characterize the acute response to allergen and to identify potentially novel molecular targets for pharmacological intervention in @entity565 . We therefore designed a study to identify genes whose regulation was altered following @entity10328 (OVA) challenge in the presence and absence of treatment with glucocorticoids in BALB/c @entity19 . RNA was isolated from lungs for gene profiling from 8-week-old sensitized @entity19 , 3 and 18 hours post OVA challenge on days 1, 4, and 7 of aerosol challenge. Taqman (real time RT-PCR) analysis of marker genes indicative of @entity61 ( @entity58 , @entity1312 ), eosinophil ( @entity638 , @entity639 ), @entity60 and epithelial cell ( @entity30927 ) phenotypes were used to characterize responses to allergen challenge. Histological evaluation of lungs from additional challenged animals revealed inflammatory infiltrates on days 4 and 7, but not on day 1 post challenge. We postulate that expression of @entity58 , @entity1312 and other genes by OVA at day 1 probably reflects activation of resident cells, whereas the fivefold increase in the number of regulated genes at day 7 reflects the contribution of recruited cells. Of the regulated genes, only a subset was counter-regulated by @entity619 treatment. Although regulated genes included genes in many protein families, herein we report regulation of two proteases whose role in response to OVA challenge has not been characterized. This model will be used to generate disease hypotheses for which may play an important role in initiating disease pathology in this model.

title: Molecular characterization of antigen-induced lung inflammation in a XXXX model of @entity565 .

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: Myocardial deformation imaging is used to assess regional left ventricular (LV) function. We sought to define the impact of changes in LV loading conditions on @entity296 parameters. Aortic valve replacement in @entity1 with different aortic valve pathologies was used as a model to assess the impact of preload and afterload changes. In 53 @entity1 scheduled for aortic valve replacement serial echocardiographic studies were performed preoperatively and postoperatively (within 7 days and at 6 months). Parasternal short-axis views were acquired. Using novel computer software radial and circumferential strain and strain rate were determined as parameters of @entity296 for each segment of the LV and were subsequently averaged. Immediately postoperatively there was a relative increase of radial strain by 4.5 +/- 1.8% after valve replacement for @entity472 ( @entity472 ) (P < .001), a relative decrease of 9.4 +/- 7.7% after valve replacement for @entity337 ( @entity337 [ @entity337 ]) (P < .001), and unchanged radial strain after valve replacement for @entity472 and @entity337 . During the subsequent 6 months of follow-up, there was additional relative increase of radial strain by 5.2 +/- 3.1% in the @entity472 group (P < .001), by 12.0 +/- 13.7% in the @entity337 group (P < .01), and by 5.6 +/- 3.4% in the @entity472 and @entity337 group (P < .001). Similar changes were observed for the other strain and strain rate parameters. In conclusion, @entity296 parameters change significantly immediately after aortic valve replacement for @entity472 or @entity337 indicating a dependency of determined @entity296 parameters on LV preload and afterload.

title: Impact of left ventricular loading conditions on XXXX parameters: analysis of early and late changes of @entity296 parameters after aortic valve replacement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'aortic stenosis']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial deformation']

entities_list: @entity337 :: ('MESH:D001022', 'Disease') :: ['AI', 'aortic regurgitation', 'aortic insufficiency']

answer: @entity296 :: (MESH:D009202,Disease) :: ['myocardial deformation']


abstract: CONTEXT: A number of therapies have been proposed for the long-term management of corticosteroid-responsive, rapidly progressive, bilateral @entity1274 ( @entity389 [ @entity389 ]). @entity1499 has emerged as the benchmark agent but has not been rigorously evaluated for hearing improvement in @entity1 with @entity389 . OBJECTIVE: To assess the efficacy of long-term @entity1499 in maintaining hearing improvements achieved with glucocorticoid ( @entity229 ) therapy in @entity1 with @entity389 . DESIGN, SETTING, AND @entity1 : A randomized, double-blind, placebo-controlled trial conducted from February 3, 1998, to November 5, 2001, of 67 @entity1 with rapidly progressive, bilateral @entity1274 at 10 tertiary care centers in the United States. INTERVENTION: Randomization to either oral @entity1499 (15 to 20 mg/wk; n = 33) or placebo (n = 34), in combination with an 18-week @entity229 taper. Follow-up examinations, including audiometric evaluation, were performed at 4, 8, 12, 24, 36, 48, and 52 weeks, or until @entity393 was documented. MAIN OUTCOME MEASURE: Maintenance of hearing improvement achieved from @entity229 treatment. RESULTS: Sixty-seven @entity1 (57.8%) enrolled in the @entity229 challenge experienced hearing improvement. Twenty-five @entity1 (37%) experienced hearing improvements in both ears. Of the individuals who reached study end points, 24 (80%) of 30 end points were because of measured @entity393 in the @entity1499 group and 29 (93.5%) of 31 end points were because of measured @entity393 in the placebo group (P =.15). @entity1499 was no more effective than placebo in maintaining the hearing improvement achieved with @entity229 treatment (hazard ratio, 1.31; 95% confidence interval, 0.79-2.17; P =.30). CONCLUSION: @entity1499 does not appear to be effective in maintaining the hearing improvement achieved with @entity229 therapy in @entity1 with @entity389 .

title: Treatment of corticosteroid-responsive @entity389 with XXXX : a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss']

entities_list: @entity389 :: ('MESH:D007759', 'Disease') :: ['autoimmune inner ear disease', 'AIED']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate', 'methotrexate']

answer: @entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']


abstract: Given that combination therapy with @entity1780 plus fibrate confers a risk of @entity121 , it is worthwhile to determine whether statin or fibrate monotherapy is associated with greater clinical benefit in individuals with @entity5703 . In this randomized double-blind study, we compared the efficacy of @entity3413 and @entity3724 on indexes of endothelial function ( @entity384 ( @entity384 ) of the brachial artery) and inflammatory markers (plasma high-sensitivity @entity1851 ( @entity1851 ), @entity1356 ( @entity1356 ), soluble @entity2936 , and soluble @entity2936 ligand (sCD40L) levels), as surrogate indicators of future @entity301 ( @entity301 ), in @entity1 with @entity5703 . A total of 70 @entity1 with plasma @entity412 levels between 200 and 500 mg/dl and total @entity165 levels of >200 mg/dl were randomly assigned to receive either @entity3413 (20 mg/day) (n=35) or micronized @entity3724 (200 mg/day) (n=35) for 8 weeks. Treatment with @entity3413 was associated with significantly greater reduction of total @entity165 and low-density lipoprotein @entity165 (LDL-C), while the decrease in @entity1674 was significantly greater in @entity1 receiving @entity3724 . Both @entity3724 and @entity3413 markedly reduced plasma levels of high-sensitivity @entity1851 , @entity1356 , and sCD40L, and improved endothelium-dependent @entity384 without mutual differences. The changes in plasma inflammatory markers did not correlate with baseline clinical characteristics in both groups. However, the improvement in @entity384 with @entity3724 treatment correlated inversely with baseline high-density lipoprotein @entity165 (HDL-C) levels, whereas the improvement in @entity384 with @entity3413 treatment was positively related to HDL-C levels. Accordingly, in the subgroup with a baseline HDL-C of < or =40 mg/dl, only @entity3724 significantly improved the endothelium-dependent @entity384 . On the other hand, in the subgroup with HDL-C >40 mg/dl, only treatment with @entity3413 achieved significant improvement in @entity384 . The data here indicate that in @entity1 with @entity5703 , both @entity3724 and @entity3413 have comparative beneficial effects on various inflammatory markers and differential beneficial effects on endothelial function according to baseline HDL-C levels. These findings should be validated by additional prospective studies, in which @entity1 are stratified by baseline HDL-C prior to randomization.

title: Efficacy of @entity3724 and @entity3413 on endothelial function and inflammatory markers in XXXX with @entity5703 : relations with baseline lipid profiles.

entities_list: @entity5703 :: ('MESH:D006950', 'Disease') :: ['combined hyperlipidemia']

entities_list: @entity3724 :: ('MESH:D011345', 'Chemical') :: ['fenofibrate']

entities_list: @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin']

entities_list: @entity1356 :: ('3553', 'Gene') :: ['interleukin-1 beta', 'IL-1 beta']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['flow-mediated dilation', 'FMD']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Households are one of the major settings of @entity683 transmission in the community and transmission is frequently initiated by school-aged @entity1 . We surveyed households with primary school (PS) and/ or junior high school (JH) @entity1 for the 2012-13 @entity683 season in Odate, Japan then characterized the epidemiology of @entity683 household transmission as well as estimated the serial intervals. METHODS: We delivered a self-reported questionnaire survey to households with PS and/or JH school @entity1 in Odate City, Japan. @entity778 predominantly circulated during the 2012-13 @entity683 season. We investigated the epidemiological characteristics of within-household transmission and calculated the serial intervals (SI). SIs were drew by a non-parametric model and compared with parametric models by the Akaike Information Criterion. The covariable contributions were investigated by the accelerated failure model. RESULTS: Household @entity683 transmission was identified in 255 out of 363 household respondents. Primary school (PS) @entity1 accounted for 45.1 % of primary cases, and disease transmission was most commonly observed between PS @entity1 and parents, followed by transmission from PS @entity1 to siblings. In primary cases of PS or JH @entity1 , younger age and longer absence from school were significantly associated with household transmission events. The mean SI was estimated as 2.8 days (95 % confidence interval 2.6-3.0 days) in the lognormal model. The estimated acceleration factors revealed that while secondary school age and the absence duration > 7 days were associated with shorter and longer SIs, respectively, antiviral prescriptions for primary cases made no contribution. CONCLUSIONS: High frequencies of household transmission from primary school with shorter SI were found. These findings contribute to the development of future mitigation strategies against @entity683 transmission in Japan.

title: Analysis of @entity683 transmission in the households of primary and junior high school students during the 2012-13 XXXX season in Odate, Japan.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['Influenza A (H3N2) virus']

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza']


abstract: OBJECTIVES: @entity414 (UA) is a strong marker of @entity65 . Therefore, we aimed to determine the relationship between serum UA levels and @entity65 in @entity1 in the early period of their acute @entity583 . STUDY DESIGN: This retrospective study included 586 consecutive @entity1 with @entity583 ( @entity583 ) who were admitted to the hospital between March 2010 and February 2012. The study population was divided into two groups; the first group included @entity9503 @entity1 (n=107; @entity414 level >6 mg/dl in @entity1 and >7 mg/dl in @entity1 ), and the second group included @entity1 with normal UA level (n=479). Multivariate analysis was used to demonstrate the predictive value of UA levels in groups. RESULTS: @entity1 in the @entity9503 group were older (median 66 years vs. 60 years, p=0.001), and the ratio of female @entity1 was higher (35.5% vs. 16.9%, p=0.001). @entity1 with @entity5052 had a significantly higher incidence of in-hospital cardiovascular mortality than the normal group (15.9% vs. 3.1%, p<0.001). @entity712 (class >=  3) was more frequent among @entity9503 @entity1 (17.8% vs. 8.8%, p=0.006). Age >=  70 years, @entity662 duration >6 hours and @entity5052 (hazard ratio (HR): 1.83, 95% confidence interval: 1.02-3.27; p=0.041) were found to be independent predictors of advanced @entity712 . @entity5052 was found to be an independent predictor of in-hospital cardiovascular mortality in multivariate analyses (HR: 5.32, 95% confidence interval: 2.46-11.49; p=0.001). CONCLUSION: This study showed that a high serum UA level is an independent predictor of cardiovascular mortality and morbidity during the in-hospital period of @entity583 .

title: The association between serum XXXX level and @entity712 and mortality in the early period of ST-elevation acute @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity9503 :: ('MESH:C537696', 'Disease') :: ['hyperuricemic']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['Advanced heart failure', 'heart failure']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia', 'Hyperuricemia']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-elevated myocardial infarction', 'myocardial infarction']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease', 'cardiovascular events']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['Uric acid', 'uric acid']

answer: @entity414 :: (MESH:D014527,Chemical) :: ['uric acid']


abstract: PURPOSE: This randomized, multicenter, phase III study compared @entity632 and @entity1205 ( @entity1129 ) with @entity632 and @entity786 (AC) as first-line chemotherapy (CT) in @entity0 ( @entity0 ). @entity1 AND METHODS: @entity1 (n = 429) were randomly assigned to receive @entity632 50 mg/m(2) plus @entity1205 75 mg/m(2) (n = 214) or @entity632 60 mg/m(2) plus @entity786 600 mg/m(2) (n = 215) on day 1, every 3 weeks for up to eight cycles. RESULTS: @entity1054 ( @entity1054 ; primary end point) and time to treatment failure (TTF) were significantly longer with @entity1129 than AC (median @entity1054 , 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048). The overall response rate (ORR) was significantly greater for @entity1 taking @entity1129 (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009). The ORR was also higher with @entity1129 in @entity1 with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%). Overall survival (OS) was comparable in both arms. Grade 3/4 @entity1398 was frequent in both groups, although @entity1398 and @entity281 were more frequent for @entity1 taking @entity1129 (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01). Severe nonhematologic @entity137 was infrequent in both groups, including grade 3/4 @entity299 ( @entity1129 , 3%; AC, 4%). CONCLUSION: @entity1129 significantly improves @entity1054 and ORR compared with AC in @entity1 with @entity0 , but there is no difference in OS. @entity1129 represents a valid option for the treatment of @entity0 .

title: @entity1205 and @entity632 compared with XXXX and @entity786 as first-line chemotherapy for @entity0 : results of a randomized, multicenter, phase III trial.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer', 'MBC']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'Time to progression']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']


abstract: BACKGROUND: The prognostic role of @entity101 on long-term survival after percutaneous coronary intervention (PCI) is limited and inconsistent. We hypothesize that @entity101 increases long-term mortality after PCI. METHODS: We analyzed data from SCAAR (Swedish Coronary Angiography and Angioplasty Registry) for all consecutive @entity1 admitted coronary care units in Sweden between January 1995 and May 2013 and who underwent PCI due to @entity583 ( @entity583 ), non- @entity583 (NSTEMI)/unstable @entity951 (UA) or stable @entity951 . We used Cox proportional-hazards regression for statistical modelling on complete-case data as well as on imputed data sets. We used interaction test to evaluate possible effect-modulation of @entity101 on risk estimates in several pre-specified subgroups: age categories, gender, @entity6 , smoking and indication for PCI ( @entity583 , NSTEMI/UA and @entity5749 ). RESULTS: During the study period, 175,892 consecutive @entity1 underwent coronary angiography due to @entity583 , NSTEMI/UA or @entity5749 . 78,100 (44%) of these had @entity101 . Median follow-up was 5.5 years. After adjustment for differences in @entity1 's characteristics, @entity101 was associated with increased risk for mortality (HR 1.12, 95% CI 1.09-1.15, p   <   .001). In subgroup analysis, risk was highest in @entity1 less than 65 years, in smokers and in @entity1 with @entity583 . The risk was lowest in @entity1 with @entity5749 (p   <   .001 for interaction test). CONCLUSION: @entity101 is associated with higher mortality in @entity1 with @entity583 , NSTEMI/UA or @entity5749 who are treated with PCI.

title: XXXX is associated with increased mortality in @entity1 with ischaemic heart disease after revascularization with percutaneous coronary intervention - a report from SCAAR.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity5749 :: ('MESH:D060050', 'Disease') :: ['stable angina']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris', 'angina']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-elevation myocardial infarction']

answer: @entity101 :: (MESH:D006973,Disease) :: ['Hypertension']


abstract: OBJECTIVE: To evaluate the efficacy and safety of meropenem in Chinese @entity1 , we conducted a study for the treatment of @entity1 with lower respiratory tract @entity281 . METHODS: A total of 182 hospitalized @entity1 were enrolled in the study. 90 @entity1 received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 @entity1 received @entity2892 / @entity9234 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7 - 14 days for both groups. RESULTS: Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving @entity2892 / @entity9234 were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the @entity2892 / @entity9234 group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from @entity1 produced beta-lactamases. @entity137 were evaluated in 72 cases in the meropenem group and 70 cases in the @entity2892 / @entity9234 group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P > 0.05). CONCLUSION: Meropenem is effective and safe for the treatment of @entity2348 caused mainly by beta-lactamase-producing strains.

title: A randomized, controlled clinical trial on meropenem versus XXXX / @entity9234 for the treatment of @entity2348 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Adverse drug reactions']

entities_list: @entity9234 :: ('MESH:D015377', 'Chemical') :: ['cilastatin']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections, urinary tract infections and other infections']

answer: @entity2892 :: (MESH:D015378,Chemical) :: ['imipenem']


abstract: INTRODUCTION: Any vascular access is of limited duration with many factors which influence survival in @entity1 on chronic hemodialysis (HD). @entity9427 as a marker of @entity102 is common among chronic HD @entity1 . Our aim was to analyze the survival of the primary @entity2548 ( @entity2548 ) and the risk factors which influence their patency and to test the hypothesis that @entity1 with normal values of serum proteins have lower risk of @entity177 compared to @entity1 with @entity9427 . METHODS: Seven hundred thirty-four consecutive @entity1 were included who underwent creation of an AVF. The @entity1 were prospectively followed-up for 2 years. Only @entity1 with AVF function after a month from its creation were analyzed. The @entity1 were divided into two subgroups, with normal and low serum protein levels (<65 g/L). FINDINGS: At follow-up 497 (67.7%) @entity2548 were still functional while 237 (32.3%) @entity2548 failed due to @entity715 or @entity850 . Serum proteins and @entity2548 created on the forearm were positive predictors while @entity6 was a negative predictor of longer AVF survival (P   <   0.001; P   =   0.003; P   =   0.043). When comparing @entity1 with normal and low serum protein levels (<65 g/L), mean survival time was significantly longer in @entity1 with normal serum levels (P   <   0.001). DISCUSSION: In this study, @entity9427 was an independent prognostic marker for @entity177 at 2 years. @entity9427 , based on our results, is an independent, more sensitive and prognostic marker of possible vascular access failure than the presence of other common factors which influence shorter AVF survival.

title: @entity9427 as a prognostic risk factor for XXXX .

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illness']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['AVF failure']

entities_list: @entity9427 :: ('MESH:D007019', 'Disease') :: ['Hypoproteinemia', 'hypoproteinemia']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity2548 :: ('MESH:D001164', 'Disease') :: ['AVFs', 'arteriovenous fistula']

answer: @entity2548 :: (MESH:D001164,Disease) :: ['arteriovenous fistula failure']


abstract: OBJECTIVE: To examine the incidence of @entity3465 luteinization in individuals undergoing hMG with IUI therapy, the association between @entity3465 luteinization, cycle fecundity, and pregnancy outcome, and to determine if the selective use of @entity3086 (LA) in @entity1 demonstrating @entity3465 luteinization improves pregnancy outcome in subsequent hMG with IUI cycles. DESIGN AND SETTING: Retrospective analysis of superovulation cycles from January 1990 until December 1991 at the University of Connecticut Health Center. @entity1 : All @entity1 with ovulatory function undergoing hMG superovulation with IUI. INTERVENTIONS: All @entity1 were tested for evidence of @entity3465 luteinization. Those demonstrating @entity3465 luteinization were started on LA in the luteal phase in their subsequent hMG with IUI cycle. MAIN OUTCOME MEASURES: Peak serum E2, the number of mature preovulatory follicles, the number of ampules of hMG, days of hMG therapy, cycle fecundity, and @entity2208 rate. RESULTS: Thirty-three percent of all hMG with IUI @entity1 showed evidence of @entity3465 luteinization, with @entity3465 luteinization occurring in 22.2% of conception cycles and 37.4% of nonconception cycles. For those @entity1 who demonstrated @entity3465 luteinization in their conception cycle, 90.0% of the pregnancies ended with either @entity2208 or were biochemical in nature compared with 44.3% in the cycles without evidence of @entity3465 luteinization. Cycle fecundity was 11.1% in @entity1 demonstrating @entity3465 luteinization compared with 26.3% for @entity1 without @entity3465 luteinization. All @entity1 demonstrating @entity3465 luteinization and not conceiving were placed on LA in the luteal phase and had a subsequent cycle fecundity of 18.9% with the percent pregnancy wastage being significantly less (33.3% versus 90.0%) when LA was used. CONCLUSIONS: Premature luteinization is a common occurrence during hMG therapy and is associated with decreased cycle fecundity and an increased incidence of @entity2208 and biochemical pregnancies. The selective use of LA in those individuals demonstrating @entity3465 luteinization results in a significant increase in the percent of @entity1 conceiving a viable pregnancy.

title: Selective use of @entity3086 in XXXX undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS']

entities_list: @entity3086 :: ('MESH:D016729', 'Chemical') :: ['leuprolide acetate']

entities_list: @entity2208 :: ('MESH:D000022', 'Disease') :: ['spontaneous abortion']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['premature']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: Asthma continues to be a substantial cause of morbidity. Various educational programmes have shown an increase in knowledge and self-management skills of @entity748 @entity1 and also revealed a reduction of severe attacks, hospitalisations and days lost from work. METHODS: A self-care manual on @entity565 was prepared. A total of 523 @entity565 @entity1 were enrolled in the study. Out of these, 260 @entity1 were included in the study group to whom self-care manual was provided and 263 were included in the control group to whom no specific instructions were given. After the initial interview (0 week), follow up of all the @entity1 was carried out at two weeks, six months and at one year. RESULTS: Out of the enrolled @entity1 , 240 (92.31%) and 240 (91.25%), 212 (81.54%) and 210 (79.85%), and 204 (78.46%) and 194 (73.76%) @entity1 completed the follow up at two weeks, six months and one year in the two groups, respectively. Various parameters analysed were knowledge of the @entity1 , their symptomatology, various triggering factors which were inducing and/or precipitating symptoms, the self-care measures they adopted at the time of acute attacks and the indices of @entity565 morbidity during the last one year. The knowledge scores were significantly higher at all the three follow up visits (F = 633. 98, p < 0.001) as compared to the baseline in the study group @entity1 . In both the groups, the symptom scores decreased at all the follow up visits (F = 71.78, p < 0.001 in the study group and F = 24.19, p < 0.001 in the control group). Multiple logistic regression analysis showed a significant improvement in knowledge and symptoms in the study group as compared to controls after adjusting for various confounding variables (p < 0.001). The number of @entity1 whose symptoms were induced and/or precipitated by exposure to various triggering factors was significantly reduced in study group for all the triggers. There was a statistically significant decrease in the number of severe attacks, number of emergency visits and need of injections during last one year in both the groups, though the differences were more marked in the study group. However, there was a significant decrease in hospital admissions and absence from school/or job in the study group at one year as compared to the control group. CONCLUSION: The self-care manual was effective in self-management of @entity565 .

title: Evaluation of self-care manual in XXXX .

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['bronchial asthma', 'asthma']

answer: @entity565 :: (MESH:D001249,Disease) :: ['bronchial asthma']


abstract: OBJECTIVE: To review our experience with periductal @entity1271 and address the clinical characteristics, management and outcome. METHODS: A retrospective study was carried out at Princess Basma Teaching Hosptal, Irbid, Jordan. Thirty-five @entity1 with the diagnosis of periductal @entity1271 from the year 1994 through to 2000 were reviewed. @entity1 presenting with periareolar non-lactating @entity32 , a periareolar inflammatory mass, abscess, mammary fistula, or nipple inversion were included in the study. RESULTS: The mean age was 33 years. @entity158 and pus nipple discharge were the most frequent symptoms. A periareolar mass, induration, mammary duct fistula, or @entity85 were found in 49%, 43%, 11%, and 34% of the cases. Twenty-six percent were smokers. This ratio increased to 75% among @entity1 with mammary fistulas. Three @entity1 had @entity272 ; the same bacterial strains were isolated from both lesions. This may suggest that breast manipulation, transferring bacteria to the breasts from other parts of the body, might play a role in the etiology. Broad spectrum antibiotics treated all @entity1 . Surgery was necessary for 32 (91%) @entity1 . CONCLUSION: @entity1271 is rare and affects non-lactating @entity1 during their reproductive life. Etiologically, periductal @entity1271 is related to @entity2348 and smoking. It mimics other serious @entity1558 including @entity189 . On the contrary, @entity1157 affects @entity1 between the ages of 42-85 years and is considered an ageing phenomenon which is not related to @entity295 or smoking.

title: XXXX . Clinical characteristics and outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1157 :: ('MESH:D001649', 'Disease') :: ['duct ectasia']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infection']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['synchronous skin lesions']

entities_list: @entity1271 :: ('MESH:D008413', 'Disease') :: ['mastitis', 'Periductal mastitis']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['nipple deformity']

entities_list: @entity1558 :: ('MESH:D001941', 'Disease') :: ['breast disorders']

answer: @entity1271 :: (MESH:D008413,Disease) :: ['Periductal mastitis']


abstract: Studies have investigated the role of hospital and surgeon case volume in outcome after @entity1755 repair (rAAA). Few have analyzed the learning curve of an individual surgeon. The purpose of this study was to analyze this learning curve in reducing morbidity and mortality after rAAA repair. Thirty-two consecutive @entity1 who underwent rAAA repair during the initial 2.5 years of a vascular surgeon's career were reviewed retrospectively. They were divided temporally into two groups of 16 @entity1 (groups 1 and 2). Outcome measures included mortality, postoperative @entity583 , @entity64 , and renal and @entity1576 . Perioperative variables previously associated with increased mortality were analyzed. The cumulative sum (CUSUM) method was used to analyze the learning curve with respect to published acceptable event rates and predetermined 80% alert and 95% alarm boundary lines. Groups 1 and 2 did not differ statistically in age, preoperative blood pressure, hemoglobin or @entity1011 . There was no difference in transfusion requirements (6.8 +/- 1.2 units vs. 6.4 +/- 1.0 units; p = 0.78), urine output (340 +/- 65 mL vs. 389 +/- 94 mL; p = 0.72) or clamp position. There was no difference in the incidence of postoperative @entity583 , @entity64 , or respiratory or @entity177 . Thirty-day mortality in group 2 was 12% as compared to 50% in Group 1 (p = 0.03). On CUSUM analysis, the cumulative failure rate in group 2 progressed lower than the 80% reassurance line, indicating improved results with time. Mortality after rAAA repair decreased over time during an early period of an individual surgeon's career. The CUSUM method is a valuable tool in analyzing an individual surgeon's experience and shows promise in quality control in vascular surgery.

title: A CUSUM analysis of XXXX repair.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1755 :: ('MESH:D001019', 'Disease') :: ['ruptured abdominal aortic aneurysm']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity1755 :: (MESH:D001019,Disease) :: ['ruptured abdominal aortic aneurysm']


abstract: AIMS AND OBJECTIVE: The aim of this study was to describe and interpret the essential meaning of the lived experiences of being in a @entity3124 -recovery process after a life-threatening condition. BACKGROUND: The @entity3124 -recovery process after a life-threatening condition takes several years and does not only include @entity1 ' experiences during intensive care. Previous research has mainly focused on what critically ill @entity1 recall. However, from a phenomenological point of view, experiences are more than memories alone. To plan and perform relevant health care and social support for @entity1 who have survived a life-threatening condition, a more profound understanding about their lived experiences is needed. DESIGN AND METHOD: In this qualitative study, a phenomenological hermeneutical  approach was used. Interviews were conducted with seven @entity1 , two to four years after they had received care in an intensive care unit in Sweden. RESULTS: The comprehensive understanding of the results shows that the @entity3124 -recovery process after a life-threatening condition means an existential struggle to reconcile with an unfamiliar body and with ordinary life. This can be understood as an 'unhomelikeness' implying a struggle to create meaning and coherence from scary and fragmented memories. The previous life projects, such as work and social life become unfamiliar when the @entity1 's fragile and weak body is disobedient and brings on altered sensations. CONCLUSIONS: @entity1 who survive a life-threatening condition have an immense need for care and support during the entire @entity3124 -recovery process, and also after the initial acute phase. They need a coherent understanding of what happened, and support to be able to perform their changed life projects. RELEVANCE TO CLINICAL PRACTICE: Supporting and caring for @entity1 ' recovery from a life- threatening condition involves recognising the @entity1 ' struggle and responding to their existential concerns.

title: Being in a XXXX -recovery process: a phenomenological hermeneutical study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patients']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critical illness']

answer: @entity3124 :: (MESH:D016638,Disease) :: ['critical illness']


abstract: BACKGROUND/AIMS: We evaluated the role and mechanisms by which the GH/ @entity2135 @entity2270 modulates cholangiocyte proliferation. METHODS: @entity14023 ( @entity14023 ), @entity2135 , @entity9929 (binding protein 3), @entity7814 substrates (IRS) were evaluated in cholangiocytes of normal or bile duct-ligated (BDL) @entity35 livers. The effects of GH and @entity2135 on proliferation of normal quiescent cholangiocytes and the transduction pathways involved were investigated. RESULTS: @entity2135 , @entity14023 , @entity7814 , @entity46332 were expressed in normal cholangiocytes and overexpressed in cholangiocytes proliferating after BDL which also secrete @entity2135 in a higher amount than normal cells. @entity9929 , which may counter-regulate @entity2135 effects, was decreased in BDL cholangiocytes. @entity2135 promoted cholangiocyte proliferation in association with overexpression of p-IGF1R, @entity24577 , @entity25251 , p-ERK1/2 and p-AKT. GH induced @entity2135 expression and release in isolated cholangiocytes, and reproduced the effects of @entity2135 but GH effects were abolished by @entity7814 blocking antibody, suggesting @entity2135 as a mediator of GH. Finally, @entity2135 and @entity53 reciprocally potentiated their proliferative effects on cholangiocytes, and by interacting at both receptor and post-receptor levels. CONCLUSIONS: Cholangiocytes respond to GH with production and release of @entity2135 that modulates cell proliferation by transduction pathways involving @entity7814 , @entity46332 and both @entity2509 and PI3-kinase pathways. The biliary epithelium is a target of GH/ @entity2135 liver @entity2270 .

title: The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 XXXX .

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol']

answer: @entity2270 :: (MESH:C566610,Disease) :: ['axis']


abstract: BACKGROUND: Primary @entity706 are very rare. The diagnosis is based on a histopathological examination and imaging studies where other disease foci should be excluded. The @entity706 are most often found in the axial skeleton, pelvis, femur and humerus. The @entity5 causes extensive @entity79 with soft tissue infiltration. Surgical treatment is currently not used routinely. The aim of this study was to present five clinical cases and their most characteristic imaging features. MATERIAL AND METHODS: Over the last three years, 1327 @entity1 with @entity5 have been hospitalized in the Oncological Orthopaedics Department in Brzoz  w, and most of these @entity5 (1184) were @entity5 . A total of 57 primary @entity5 were diagnosed, of which five fulfilled the diagnostic criteria of primary @entity706 . @entity1 age and @entity5 sites varied. All the @entity5 were large, infiltrated soft tissues and caused @entity3061 . No periosteal reactions or sequesters were observed. Two @entity1 were treated surgically by radical resection and implantation of a prosthesis. The indication for surgery was @entity5 location enabling R0 resection. All @entity1 received chemotherapy and radiotherapy. They have been followed up at the haematological and orthopaedic clinics. There is currently no evidence of generalized disease. RESULTS: The most characteristic feature of @entity706 is extensive @entity3061 with soft tissue infiltration. The absence of false capsules helps distinguish @entity706 from @entity242 . No bone sequesters or @entity75 described in the literature were observed in imaging examinations at our centre. Discussion. Diagnosis of a primary @entity706 is difficult as the @entity5 often resembles metastatic lesions. Secondary bone involvement is particularly difficult to differentiate from @entity706 . The Coley criteria are useful in diagnosis. If radical resection is possible, surgical treatment significantly improves prognosis. Radiotherapy has been associated with frequent recurrences of generalized disease and it is postulated that it should only be employed in palliative @entity1 . CONCLUSIONS: 1. Primary @entity706 are rare @entity5 . 2. Imaging studies characteristically show extensive @entity79 with soft tissue infiltration. 3. No @entity75 or periosteal reactions were observed. 4. Surgical treatment should be performed when radical @entity5 resection is possible.

title: Primary XXXX - experience of oncological orthopaedics department in Brzoz  w.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['bone lymphoma', 'bone lymphomas', 'multifocal lymphoma', 'lymphomas']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'bone tumours', 'tumours', 'malignant bone tumours', 'metastatic cancers']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['sclerotic lesions', 'osteosclerotic lesions']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['lytic bone destruction']

entities_list: @entity3061 :: ('MESH:D010014', 'Disease') :: ['osteolysis']

answer: @entity706 :: (MESH:D008223,Disease) :: ['bone lymphoma']


abstract: BACKGROUND: Vagus nerve stimulation (VNS) is an adjunctive neurophysiological treatment for those @entity1 who have pharmacoresistant or surgically resistant partial onset @entity302 . OBJECTIVE: The aim of this study is to determine the effects of high and low stimulation paradigms on a responder rate of >= 50 and >= 75  % reduction in @entity410 frequency and associated adverse effects in adults and @entity1 . METHOD: A literature search was performed using Medline, PubMed, EMBASE, and Cochrane library for studies using vagus nerve stimulation published from January 1980 until July 2014 for medically or surgically resistant partial onset @entity410 , in @entity1 and adults. No restrictions on languages were imposed. DATA COLLECTION AND ANALYSIS: Four authors reviewed and selected studies for inclusion and exclusion. The search identified five randomized control trials that fit with our inclusion criteria. The following outcomes were evaluated: 50  % or greater reduction in total @entity410 frequency, 75  % or greater reduction in total @entity410 frequency, and adverse effects. RESULTS: Four randomized controlled trials were analyzed in this meta-analysis. Results indicate high stimulation is more effective in adult @entity1 who experienced >= 50 and >= 75  % reduction in @entity410 frequency with a significant difference within both high and low stimulation groups. In @entity1 , there was no significant difference between the two groups and @entity1 with >= 50  % reduction in @entity410 . Adverse effects such as hoarseness and @entity1353 were more common in the high stimulation group where the remaining side effects were not statistically different among both groups. CONCLUSION: High stimulation is more effective than low stimulation in producing a greater reduction in @entity410 frequency in @entity1 with medically and surgically resistant @entity302 .

title: Meta-analysis of vagus nerve stimulation treatment for XXXX : correlation between device setting parameters and acute response.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: In @entity1 medicine @entity56 is a well-established side-effect of the therapeutic use of antibiotics, especially the @entity7660 . Side-effects caused by @entity7187 are uncommon and only a very few of these seem to be caused by allergic mechanisms. Clinically, @entity56 is characterized by a spectrum of reactions ranging from mild @entity1910 to @entity4 or life-threatening anaphylaxis. Concern has been expressed that antibiotic residues in meat and other foods might be responsible for similar @entity56 in a small number of individuals. This review assesses the potential risk of such reactions in general, but focuses on @entity566 to @entity114 and @entity7646 residues in particular. In relation to the risk of primary sensitization, it is unlikely that residues could contribute to the overall immune response in view of the very low levels that are likely to be encountered in comparison with the high levels received during therapeutic use. No evidence has been found that any individual has become sensitized by residues of either penicillins or @entity7187 . Furthermore, the oral route is much less sensitizing than parenteral administration and immunochemical studies with @entity114 indicate that hapten-protein complexes formed in vivo are unlikely to be immunogenic because of their low dose, low epitope density and binding to autologous carrier proteins. For performed allergens, the epitope density was also too low to be immunogenic. Because of the ubiquitous nature of @entity114 -producing moulds in nature and the extensive use of @entity3405 antibiotics in @entity1 medicine, it is unlikely that epidemiological studies could be undertaken that could allow quantification of the minimal risk. The risk of @entity56 in pre-sensitized individuals can be assessed similarly and again it is concluded that factors such as dose, oral administration and low epitope density make it unlikely that a significantly antigenic derivative could be formed. However, a review of the literature on @entity114 hypersensitivity revealed a very small number of previously sensitized individuals from whom there is reasonable clinical and documentary evidence that @entity114 residues in milk triggered an @entity56 , usually a @entity1910 . Although these cases are very rare (less than 10 cases reported in the last 25 years), they illustrate the continuing need to control antibiotic residues vigilantly. Animal models have not proved useful for predicting the risk of @entity56 to drugs, since @entity566 in @entity1 is determined by genetic and other factors and no validated methods exist to determine a no-effect level.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Risk assessment of antibiotic residues of @entity7660 and XXXX in food products with regard to their immuno-allergic potential.

entities_list: @entity1910 :: ('MESH:D005076', 'Disease') :: ['skin rashes', 'rash']

entities_list: @entity7646 :: ('CHEBI:25106', 'Chemical') :: ['macrolide']

entities_list: @entity3405 :: ('CHEBI:35627', 'Chemical') :: ['beta-lactam']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['angio-oedema']

entities_list: @entity114 :: ('MESH:D010406', 'Chemical') :: ['penicillin']

entities_list: @entity7660 :: ('MESH:D047090', 'Chemical') :: ['beta-lactams']

entities_list: @entity7187 :: ('MESH:D018942', 'Chemical') :: ['macrolides']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['drug allergy', 'hypersensitivity reactions', 'allergic reaction', 'allergic reactions']

answer: @entity7187 :: (MESH:D018942,Chemical) :: ['macrolides']


abstract: INTRODUCTION: The combined role of atrial septal lead location and atrial pacing algorithms in the prevention of @entity4710 ( @entity1129 /AF), including both @entity955 and flutter, is unknown. We tested the hypothesis that atrial prevention pacing algorithms could decrease @entity1129 /AF frequency in @entity1 with @entity118 , @entity1168 , and paroxysmal @entity1129 /AF. METHODS AND RESULTS: A total of 298 @entity1 (age 70 +/- 10 years; 61% male) from 35 centers were implanted with a DDDRP pacing system including three @entity1129 /AF prevention pacing algorithms. Lead site was randomized at implant to right atrial septal or nonseptal. @entity1 were randomized 1 month postimplant to @entity1129 /AF prevention ON or OFF for 3 months and then crossed over for 3 months. @entity1 logged symptomatic @entity1129 /AF episodes via a manual activator. Prevention efficacy was evaluated based on intention-to-treat in 277 @entity1 (138 septal) with complete follow-up. No changes in device-recorded @entity1129 /AF frequency or burden were observed with algorithms OFF versus ON or between @entity1 randomized to septal versus nonseptal lead location. Analysis of other secondary outcomes revealed that @entity1129 /AF prevention pacing resulted in decreased @entity11706 in both the septal (1.9 [0.2-8.7] vs 3.3 [0.3-10.6]x 103/day; P < 0.01) and nonseptal groups (0.9 [0.2-3.3] vs 1.3 [0.3-5.5]x 103/day; P < 0.001). @entity1 with septal leads had fewer symptomatic @entity1129 /AF episodes ON versus OFF (1.4 +/- 3.0 vs 2.5 +/- 5.2/month, P = 0.01). CONCLUSION: The combination of three atrial prevention pacing algorithms did not decrease device classified @entity4710 frequency or burden during a 3-month cross-over period in bradycardic @entity1 and septal or nonseptal atrial pacing leads. Prevention pacing was associated with decreased frequency of @entity11706 and with decreased symptomatic @entity4710 frequency in @entity1 with @entity118 .

title: Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity11706 :: ('MESH:D018880', 'Disease') :: ['atrial premature contractions', 'premature atrial contractions']

entities_list: @entity118 :: ('MESH:D006344', 'Disease') :: ['atrial septal leads']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['atrial tachyarrhythmia', 'atrial tachyarrhythmias']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity4710 :: (MESH:D013617,Disease) :: ['atrial tachyarrhythmia']


abstract: OBJECT: Peripheral motor axons can regenerate through motor endoneurial tubes of foreign nerves to reinnervate different target muscles. This regenerative capacity has been brought to clinical applications for restorative surgery after nerve or root injury. In this study the authors explore the extent to which nerve @entity129 and lumbar ventral roots would be effective in inducing reinnervation of paralyzed hindlimb muscles after spinal cord hemisection at the thoracolumbar boundary in @entity35 . METHODS: The proximal extremities of sectioned intercostal nerves T10-12 were surgically connected to the distal extremities of sectioned ipsilateral lumbar ventral roots L3-5, respectively. Motor activity reappeared 2 months postsurgery; however, locomotion was not restored and inappropriate motor patterns persisted at 9 months postsurgery. At that time, data from electrophysiological and histological studies and horseradish peroxidase retrograde labeling demonstrated efficient regrowth of thoracic motor neuron axons that reached hindlimb muscles. They also revealed a persistent @entity154 of regrown fibers, as shown by size heterogeneity and presumable extensive axonal branching. These features are consistent with reduced neural activity subsequent to continuing inappropriate motor patterns. CONCLUSIONS: These results indicate that @entity129 with lumbar ventral roots allows efficient reinnervation of paralyzed hindlimb muscles after spinal cord hemisection in @entity35 . Stimulating the reorganization of the neuronal circuitry in the central nervous system by locomotion training or other methods would presumably result in both functional and anatomical improvements. This experimental setting provides a convenient animal model to investigate these processes.

title: Efficient reinnervation of hindlimb muscles by thoracic motor neurons after nerve cross-anastomosis in XXXX .

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['cross-anastomosis between lower intercostal nerves', 'cross-anastomosis of intercostal nerves']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['maturation defect']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: The occurrence of @entity1163 is a very frequent event. In the absence of a structural @entity299 , @entity1163 is resulting of an anomalous @entity65 mediated by the autonomic nervous system. It is the final common manifestation of different abnormal mechanisms and is frequently precipitated by orthostatism. Orthostatic intolerance syndrome refers to the development of symptoms during the upright posture that disappear in supine position. @entity591 may be one of the clinical features of the syndrome. During orthostatic stress a hyperadrenergic response, with maintained increment of heart rate and associated symptoms, is developed. Changes in blood pressure may be diverse and in some cases @entity551 and @entity1163 occurs. Eight @entity1 with symptoms of orthostatic intolerance who underwent autonomic evaluation and were diagnosed from @entity591 are presented. In all the cases an abnormal increment of heart rate during tilting was found and it was associated to @entity1109 . Evidence of restricted sympathetic impairment was observed in six cases with distal reduction of sudomotor function and abnormal adrenergic response during Valsalva manoeuvre. Symptoms disappeared or mostly subsided with pharmacological ( @entity3659 in one case, @entity109 in another one and non-cardioselective beta-blockers in six @entity1 ) and non-pharmacological treatment. In further examinations heart rate and blood pressure were normal.

title: [Orthostatic XXXX : study of 8 @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3659 :: ('MESH:D000639', 'Chemical') :: ['amitriptyline']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['hyperadrenergic symptoms']

entities_list: @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope', 'syncopal episodes']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['postural tachycardia', 'Tachycardia']

entities_list: @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbital']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['systemic or cardiac disease']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular response neurally']

answer: @entity591 :: (MESH:D013610,Disease) :: ['postural tachycardia']


abstract: Billing data for individual @entity1 from General Practice surgeries can be used to analyse primary care utilisation. Making these data available for research and controlling purposes of the German health care system is vital for health services research. Due to the predominant billing purposes, German routine data are unlikely to yield a realistic and differentiated picture of primary care. The General Practice morbidity research network CONTENT (CONTinuous morbidity registration Epidemiologic NeTwork) was established as part of the primary care research grant of the German Federal Ministry of Research and Education. As opposed to other available German routine health care data, the project is designed around episodes of care as the ordering principle of primary care. An episode-based registration integrates the elements reason for encounter, result of the encounter and medical procedure across the quarterly billing timeframe. The use of the @entity3232 ( @entity3232 ) in the CONTENT project supports a specific adaptation to documentation in primary care. As opposed to the International Statistical Classification of Diseases, @entity204 ( @entity204 ), @entity3232 was especially developed for primary care purposes. An episode-based registration and an appropriate classification are prerequisites for a realistic and detailed picture of morbidity and services provided in primary care. An existing electronic medical record (EMR) was extended with domain-specific modules in order to meet the requirements of episode-based registration. The resulting database has already yielded analyses that were impossible to achieve from German routine health care data. Further analyses will subsequently be based on the continuously expanding database and have the potential to shed light on complex epidemiological and health economics research questions. First results point in the direction that the new mode of data collection, in contrast to routinely entered data, features the potential for a more detailed assessment concerning utilisation of medical services, morbidity, course of @entity221 and outcomes in the context of primary care.

title: [Detailed data collection regarding the utilization of medical services, morbidity, course of XXXX and outcomes by episode-based documentation in general practices within the CONTENT project].

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['Injuries, and Causes of Death', 'ICD']

entities_list: @entity3232 :: ('MESH:D008310', 'Disease') :: ['International Classification of Primary Care', 'ICPC']

answer: @entity221 :: (MESH:D005334,Disease) :: ['illness']


abstract: Determination of the optimal duration of anticoagulant treatment for @entity1211 ( @entity1211 ) is a major step in the management of @entity1 with this disease. The assessment depends on the identification of two sets of risk factors: those for recurrence after anticoagulant treatment is stopped and those for @entity548 in cases of prolonged treatment. Nonetheless, the determination of the optimal duration remains controversial. Recent data finally make it possible to clarify this decision. Recent treatment trials demonstrate that @entity1 at high risk of recurrence receive no sustained benefit from a prolonged but limited anticoagulant treatment. In other words, the choice is simplified: either the risk is low, and treatment for 3months is sufficient, or the risk is high, and treatment must be envisioned for an unlimited duration. Adequate identification of @entity1 eligible for short or unlimited treatment is more crucial than ever and depends on the presence of determinant clinical variables, as the information from laboratory or morphologic tests is generally marginal. The risk of @entity1031 recurrence is low when the initial episode is triggered by a major reversible factor, and a short treatment of 3months is thus indicated. These inducing factors are mainly surgery, lower limb injuries, immobilization for a medical condition, pregnancy, or use of combined @entity172 - @entity1871 contraceptives. Among @entity1 with @entity1211 not induced by these factors, the risk of recurrence is high and requires planning anticoagulant treatment for an unlimited duration. Nonetheless, the risk of @entity548 is a major constraint to such unlimited treatment. Accordingly, the perspectives for secondary prevention that is equally effective but has a lower risk of @entity548 are currently under evaluation. Finally, @entity1 with @entity5 are in a separate category, with a very high risk of recurrence that justifies treatment for at least 6months.

title: [Optimal duration of anticoagulant treatment after XXXX ].

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['progestin']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTED', 'venous thromboembolic disease']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolic disease']